Chinese consensus of cardio-oncology in breast cancer

Zan SHEN; Zhimin SHAO; Branch Cancer Support Rehabilitation Therapy Group of Chinese Medical Association Oncology; Treatment Consensus the Drafting Committee of China Breast Cancer Related Heart Disease Diagnosis and

doi:10.19401/j.cnki.1007-3639.2022.10.010

您当前的位置：

首页 >

文章列表页 >

Chinese consensus of cardio-oncology in breast cancer

Guideline and Consensus | 更新时间：2025-12-31

- Chinese consensus of cardio-oncology in breast cancer
- China Oncology Vol. 32, Issue 10, Pages: 1016-1036(2022)
- 作者机构：
  
  1. 上海交通大学附属第六人民医院肿瘤内科，上海 200233
  2. 复旦大学附属肿瘤医院乳腺外科，上海 200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.10.010
  CLC： R737.9
- Received：15 August 2022，
  
  Revised：2022-09-04，
  
  Published Online：30 October 2022，
- 稿件说明：
移动端阅览
Zan SHEN, Zhimin SHAO, Branch Cancer Support Rehabilitation Therapy Group of Chinese Medical Association Oncology, et al. Chinese consensus of cardio-oncology in breast cancer[J]. China Oncology, 2022, 32(10): 1016-1036.
DOI：

Zan SHEN, Zhimin SHAO, Branch Cancer Support Rehabilitation Therapy Group of Chinese Medical Association Oncology, et al. Chinese consensus of cardio-oncology in breast cancer[J]. China Oncology, 2022, 32(10): 1016-1036. DOI： 10.19401/j.cnki.1007-3639.2022.10.010.

摘要

乳腺癌和心血管疾病是现代社会的两大“杀手”，严重威胁着中国女性的健康，目前两个学科之间关联共性尚未引起临床医师足够的重视，为相关的跨学科合作实践带来一定困难。因此，对于那些已存在心血管系统疾病或心血管疾病风险的乳腺癌患者，临床医师在进行相关抗肿瘤诊疗时，应用类似乳腺癌干预策略的方法来综合评估相关风险，进行相关心脏毒性的预防及治疗干预。目前不少发达国家，已经建立了肿瘤心脏病专科门诊、病房和对应的多学科治疗团队（multidisciplinary treatment teams，MDT）。而在国内，相关学科发展才刚刚开始。可以预见的是，随着乳腺癌检测和治疗手段的不断进步，会有越来越多的乳腺癌患者获得长期的生存，这意味着其中部分患者必然要面临抗肿瘤治疗相关心脏毒性所带来的并发症的风险。因此，一份具有强有力循证医学证据支持的相关指南和临床共识能够为临床医师提供针对性的随访、监测、治疗流程和有效的管理手段，具有十分重要的临床指导意义。本共识旨在指导临床医师对乳腺癌患者进行相关抗肿瘤治疗（化疗、靶向治疗、手术、内分泌治疗、免疫治疗及放疗）的前提下，将心脏保护作为一个整体进行评估和监测，根据监测的结果决定后续干预手段，并决定是否及何时由心脏科医师进行专业会诊，避免因对乳腺癌相关心脏毒性认识不够，导致治疗不及时产生相关不良后果，为中国乳腺癌心脏病诊疗防治提供一份切实可行的临床实践操作流程，最终为改善中国乳腺癌患者的预后作出贡献。

Abstract

Recent advances in the medical oncological treatment options for cancer have led to a clear improvement in the survival rate worldwide; however

many of the recently developed new drugs are directly or indirectly associated with cardiovascular side effects. Cardiovascular diseases are already the most frequent non-cancerous cause of death in tumor patients. Prevention and early detection of these complications

correct management and timely initiation of specific cardiac medical treatment are the keys to improvement of the cardiovascular prognosis. At present

many developed countries have established oncology-cardiology specialist clinics

wards and related multidisciplinary teams (MDT). In our country

development of cardio-oncology has just on the way. With improvement of survival of breast cancer patients

it is reasonable to foresee that more and more breast cancer patients might suffer from cardiovascular disease

which indicates that it is necessary to focus on risk associated with antitumor therapy-related cardiotoxicity. Therefore

an elaborate guideline supported by solid medical evidence is strongly needed for clinicians major in oncology. This consensus provides an overview and comprehensive summary of the possible cardiotoxic side effects of important oncological therapies and offers possible practical strategies with respect to risk stratification

cardiological follow-up care and management approaches for chemotherapy-induced left ventricular dysfunction. We believe this consensus will provide a practical clinical procedures for treatment and prevention of cardio-oncology in breast cancer in China

and make contributions to improvement of outcome of cardiotoxicity in Chinese breast cancer patients.

关键词

Keywords

references

孔令泉 , 吴凯南 , 厉红元 . 乳腺肿瘤心脏病学 [M ] . 北京 : 科学出版社 , 2018 .

RAGLE D H , VILLALOBOS D A , LEZAMA F S , et al. Cardio-oncology cardiovascular toxicity and antineoplastics [J ] . Cardiovas Metab Sci , 2021 , 32 ( 1 ): 42 - 55 . DOI: 10.35366/98230 http://doi.org/10.35366/98230 https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=98230 https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=98230

PENG J , RUSHTON M , JOHNSON C , et al. An international survey of healthcare providers' knowledge of cardiac complications of cancer treatments [J ] . Cardiooncology , 2019 , 5 : 12 . DOI: 10.1186/s40959-019-0049-2 http://doi.org/10.1186/s40959-019-0049-2

MEHTA L S , WATSON K E , BARAC A , et al. Cardiovascular disease and breast cancer: Where these entities intersect: a scientific statement from the American heart association [J ] . Circulation , 2018 , 137 ( 8 ).

《中国心血管健康与疾病报告》编写组 . 《中国心血管健康与疾病报告2021》概述 [J ] . 中国心血管病研究 , 2022 , 20 ( 7 ): 577 - 596 .

The Writing Committee of China Cardiovascular Health and Disease Report . Key points of report on cardiovascular health and diseases in China 2021 [J ] . Chin J Cardiovasc Res , 2022 , 20 ( 7 ): 577 - 596 .

尹周一 , 王梦圆 , 游伟程 , 等 . 2022美国癌症统计报告解读及中美癌症流行情况对比 [J ] . 肿瘤综合治疗电子杂志 , 2022 , 8 ( 2 ): 54 - 63 .

YIN Z Y , WANG M Y , YOU W C , et al. Interpretation on the report of American cancer statistics, 2022 and comparison of cancer prevalence in China and America [J ] . J Multidiscip Cancer Manag Electron Version , 2022 , 8 ( 2 ): 54 - 63 .

刘威 , 王黎君 , 齐金蕾 , 等 . 1990—2017年中国女性乳腺癌疾病负担分析 [J ] . 中华流行病学杂志 , 2021 ( 7 ): 1225 - 1230 .

LIU W , WANG L J , QI J L , et al. Disease burden of breast cancer in women in China, 1990-2017 [J ] . Chin J Epidemiol , 2021 ( 7 ): 1225 - 1230 .

王乐 , 岳馨培 , 石菊芳 , 等 . 我国既往二十年乳腺癌经济负担研究 [J ] . 中国慢性病预防与控制 , 2017 , 25 ( 2 ): 143 - 146 .

WANG ( L /Y ), YUE X P , SHI J F , et al. Study on the economic burden of breast cancer in the past 20 years in China [J ] . Chin J Prev Control Chronic Dis , 2017 , 25 ( 2 ): 143 - 146 .

ZHENG R S , ZHANG S W , ZENG H M , et al. Cancer incidence and mortality in China, 2016 [J ] . J Natl Cancer Cent , 2022 , 2 ( 1 ): 1 - 9 .

胡崇珠 , 杨颖 , 方志沂 . 中国乳腺癌患者生活质量研究进展 [J ] . 中华乳腺病杂志(电子版) , 2010 , 4 ( 6 ): 666 - 670 .

HU C Z , YANG Y , FANG Z Y . Research progress on quality of life of breast cancer patients in China [J ] . Chin J Breast Dis Electron Ed , 2010 , 4 ( 6 ): 666 - 670 .

JONES L M , STONER L , BROWN C , et al. Cardiovascular disease among breast cancer survivors: the call for a clinical vascular health toolbox [J ] . Breast Cancer Res Treat , 2013 , 142 ( 3 ): 645 - 653 . DOI: 10.1007/s10549-013-2766-9 http://doi.org/10.1007/s10549-013-2766-9 http://link.springer.com/10.1007/s10549-013-2766-9 http://link.springer.com/10.1007/s10549-013-2766-9

马飞 , 卢雯平 , 徐兵河 . 乳腺癌全方位全周期健康管理 [M ] . 上海 : 上海科学技术出版社 , 2018 .

BRADSHAW P T , STEVENS J , KHANKARI N , et al. Cardiovascular disease mortality among breast cancer survivors [J ] . Epidemiology , 2016 , 27 ( 1 ): 6 - 13 . DOI: 10.1097/EDE.0000000000000394 http://doi.org/10.1097/EDE.0000000000000394

SWAIN S M , WHALEY F S , EWER M S . Congestive heart failure in patients treated with doxorubicin [J ] . Cancer , 2003 , 97 ( 11 ): 2869 - 2879 . DOI: 10.1002/cncr.11407 http://doi.org/10.1002/cncr.11407 https://onlinelibrary.wiley.com/doi/10.1002/cncr.11407 https://onlinelibrary.wiley.com/doi/10.1002/cncr.11407

ZHENG P P , LI J , KROS J M . Breakthroughs in modern cancer therapy and elusive cardiotoxicity: critical research-practice gaps, challenges, and insights [J ] . Med Res Rev , 2018 , 38 ( 1 ): 325 - 376 . DOI: 10.1002/med.21463 http://doi.org/10.1002/med.21463 https://onlinelibrary.wiley.com/doi/10.1002/med.21463 https://onlinelibrary.wiley.com/doi/10.1002/med.21463

CARDINALE D , IACOPO F , CIPOLLA C M . Cardiotoxicity of anthracyclines [J ] . Front Cardiovasc Med , 2020 , 7 : 26 . DOI: 10.3389/fcvm.2020.00026 http://doi.org/10.3389/fcvm.2020.00026

EVANS J D W , DOBBIN S J H , PETTIT S J , et al. High-sensitivity cardiac troponin and new-onset heart failure: a systematic review and meta-analysis of 67, 063 patients with 4, 165 incident heart failure events [J ] . JACC Heart Fail , 2018 , 6 ( 3 ): 187 - 197 . DOI: 10.1016/j.jchf.2017.11.003 http://doi.org/10.1016/j.jchf.2017.11.003 https://linkinghub.elsevier.com/retrieve/pii/S221317791730762X https://linkinghub.elsevier.com/retrieve/pii/S221317791730762X

VALCOVICI M , ANDRICA F , SERBAN C , et al. Cardiotoxicity of anthracycline therapy: current perspectives [J ] . Arch Med Sci , 2016 , 12 ( 2 ): 428 - 435 . DOI: 10.5114/aoms.2016.59270 http://doi.org/10.5114/aoms.2016.59270

BALDINI E , PROCHILO T , SALVADORI B , et al. Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety [J ] . Br J Cancer , 2004 , 91 ( 1 ): 45 - 49 . DOI: 10.1038/sj.bjc.6601883 http://doi.org/10.1038/sj.bjc.6601883 https://doi.org/10.1038/sj.bjc.6601883 https://doi.org/10.1038/sj.bjc.6601883

HEQUET O , LE Q H , MOULLET I , et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults [J ] . J Clin Oncol , 2004 , 22 ( 10 ): 1864 - 1871 .

ARMENIAN S H , SUN C L , FRANCISCO L , et al. Late congestive heart failure after hematopoietic cell transplantation [J ] . J Clin Oncol , 2008 , 26 ( 34 ): 5537 - 5543 . DOI: 10.1200/JCO.2008.17.7428 http://doi.org/10.1200/JCO.2008.17.7428

BOWLES E J , WELLMAN R , FEIGELSON H S , et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study [J ] . J Natl Cancer Inst , 2012 , 104 ( 17 ): 1293 - 1305 . DOI: 10.1093/jnci/djs317 http://doi.org/10.1093/jnci/djs317

HERRMANN J , LERMAN A , SANDHU N P , et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology [J ] . Mayo Clin Proc , 2014 , 89 ( 9 ): 1287 - 1306 . DOI: 10.1016/j.mayocp.2014.05.013 http://doi.org/10.1016/j.mayocp.2014.05.013

CHOW E J , CHEN Y , KREMER L C , et al. Individual prediction of heart failure among childhood cancer survivors [J ] . J Clin Oncol , 2015 , 33 ( 5 ): 394 - 402 . DOI: 10.1200/JCO.2014.56.1373 http://doi.org/10.1200/JCO.2014.56.1373

FLOYD J D , NGUYEN D T , LOBINS R L , et al. Cardiotoxicity of cancer therapy [J ] . J Clin Oncol , 2005 , 23 ( 30 ): 7685 - 7696 .

TAN-CHIU E , YOTHERS G , ROMOND E , et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 [J ] . J Clin Oncol , 2005 , 23 ( 31 ): 7811 - 7819 .

SPEYER J L , GREEN M D , KRAMER E , et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer [J ] . N Engl J Med , 1988 , 319 ( 12 ): 745 - 752 . DOI: 10.1056/NEJM198809223191203 http://doi.org/10.1056/NEJM198809223191203 http://www.nejm.org/doi/abs/10.1056/NEJM198809223191203 http://www.nejm.org/doi/abs/10.1056/NEJM198809223191203

VENTURINI M , MICHELOTTI A , DEL MASTRO L , et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer [J ] . J Clin Oncol , 1996 , 14 ( 12 ): 3112 - 3120 .

MARTY M , ESPIÉ M , LLOMBART A , et al. Multicenter randomized phase Ⅲ study of the cardioprotective effect of dexrazoxane (cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy [J ] . Ann Oncol , 2006 , 17 ( 4 ): 614 - 622 . DOI: 10.1093/annonc/mdj134 http://doi.org/10.1093/annonc/mdj134 https://linkinghub.elsevier.com/retrieve/pii/S0923753419575615 https://linkinghub.elsevier.com/retrieve/pii/S0923753419575615

KIM I H , LEE J E , YOUN H J , et al. Cardioprotective effect of dexrazoxane in patients with HER2-positive breast cancer who receive anthracycline based adjuvant chemotherapy followed by trastuzumab [J ] . J Breast Cancer , 2017 , 20 ( 1 ): 82 - 90 . DOI: 10.4048/jbc.2017.20.1.82 http://doi.org/10.4048/jbc.2017.20.1.82 https://ejbc.kr/DOIx.php?id=10.4048/jbc.2017.20.1.82 https://ejbc.kr/DOIx.php?id=10.4048/jbc.2017.20.1.82

HOFHEINZ R D , GNAD-VOGT S U , BEYER U , et al. Liposomal encapsulated anti-cancer drugs [J ] . Anticancer Drugs , 2005 , 16 ( 7 ): 691 - 707 . DOI: 10.1097/01.cad.0000167902.53039.5a http://doi.org/10.1097/01.cad.0000167902.53039.5a https://journals.lww.com/00001813-200508000-00002 https://journals.lww.com/00001813-200508000-00002

OLIVIERI J , PERNA G P , BOCCI C , et al. Modern management of anthracycline-induced cardiotoxicity in lymphoma patients: low occurrence of cardiotoxicity with comprehensive assessment and tailored substitution by nonpegylated liposomal doxorubicin [J ] . Oncologist , 2017 , 22 ( 4 ): 422 - 431 . DOI: 10.1634/theoncologist.2016-0289 http://doi.org/10.1634/theoncologist.2016-0289

O'BRIEN M E , WIGLER N , INBAR M , et al. Reduced cardiotoxicity and comparable efficacy in a phase Ⅲ trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer [J ] . Ann Oncol , 2004 , 15 ( 3 ): 440 - 449 . DOI: 10.1093/annonc/mdh097 http://doi.org/10.1093/annonc/mdh097 https://linkinghub.elsevier.com/retrieve/pii/S092375341964144X https://linkinghub.elsevier.com/retrieve/pii/S092375341964144X

CARDINALE D , COLOMBO A , SANDRI M T , et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition [J ] . Circulation , 2006 , 114 ( 23 ): 2474 - 2481 .

中华医学会心血管病学分会心力衰竭学组 , 中国医师协会心力衰竭专业委员会 , 中华心血管病杂志编辑委员会 . 中国心力衰竭诊断和治疗指南2018 [J ] . 中华心力衰竭和心肌病杂志(中英文) , 2018 , 2 ( 4 ): 196 - 225 .

Heart Failure Group of Cardiology Branch of Chinese Medical Association , Heart Failure Professional Committee of Chinese Medical Doctor Association , Editorial Committee of Chinese Journal of Cardiology . Chinese guidelines for diagnosis and treatment of heart failure 2018 [J ] Chin J Heart Failure Cardiomyopathy (Chinese and English) , 2018 , 2 ( 4 ): 196 - 225 .

HUANG S T , WANG Y P , CHEN Y H , et al. Liposomal paclitaxel induces fewer hematopoietic and cardiovascular complications than bioequivalent doses of Taxol [J ] . Int J Oncol , 2018 , 53 ( 3 ): 1105 - 1117 .

LIU M , LIU S Y , YANG L , et al. Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis [J ] . BMC Cancer , 2021 , 21 ( 1 ): 118 . DOI: 10.1186/s12885-021-07831-7 http://doi.org/10.1186/s12885-021-07831-7

KHATIB R , SABIR F R N , OMARI C , et al. Managing drug-induced QT prolongation in clinical practice [J ] . Postgrad Med J , 2021 , 97 ( 1149 ): 452 - 458 . DOI: 10.1136/postgradmedj-2020-138661 http://doi.org/10.1136/postgradmedj-2020-138661

DEAC A L , BURZ C C , BOCSAN I C , et al. Fluoropyrimidine-induced cardiotoxicity [J ] . World J Clin Oncol , 2020 , 11 ( 12 ): 1008 - 1017 . DOI: 10.5306/wjco.v11.i12.1008 http://doi.org/10.5306/wjco.v11.i12.1008

KÖHNE C H , THUSS-PATIENCE P , FRIEDRICH M , et al. Raltitrexed (tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity [J ] . Br J Cancer , 1998 , 77 ( 6 ): 973 - 977 . DOI: 10.1038/bjc.1998.160 http://doi.org/10.1038/bjc.1998.160 https://doi.org/10.1038/bjc.1998.160 https://doi.org/10.1038/bjc.1998.160

甲磺酸艾立布林注射液说明书 . 核准日期:2019年07月12日,修订日期:2019年09月18日. 2019, 卫材(中国)药业有限公司 .

Instruction manual of eribrin mesylate injection Approval date: July 12 , 2019; revision date: September 18, 2019 2019, Eisai (China) Pharmaceutical Co., Ltd

HUDIS C A . Trastuzumab: mechanism of action and use in clinical practice [J ] . N Engl J Med , 2007 , 357 ( 1 ): 39 - 51 . DOI: 10.1056/NEJMra043186 http://doi.org/10.1056/NEJMra043186 http://www.nejm.org/doi/abs/10.1056/NEJMra043186 http://www.nejm.org/doi/abs/10.1056/NEJMra043186

EWER S M , EWER M S . Cardiotoxicity profile of trastuzumab [J ] . Drug Saf , 2008 , 31 ( 6 ): 459 - 467 . DOI: 10.2165/00002018-200831060-00002 http://doi.org/10.2165/00002018-200831060-00002 http://link.springer.com/10.2165/00002018-200831060-00002 http://link.springer.com/10.2165/00002018-200831060-00002

EWER M S , VOOLETICH M T , DURAND J B , et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment [J ] . J Clin Oncol , 2005 , 23 ( 31 ): 7820 - 7826 .

PEREZ E A , SUMAN V J , DAVIDSON N E , et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial [J ] . J Clin Oncol , 2008 , 26 ( 8 ): 1231 - 1238 . DOI: 10.1200/JCO.2007.13.5467 http://doi.org/10.1200/JCO.2007.13.5467

SENDUR M A , AKSOY S , ALTUNDAG K . Pertuzumab-induced cardiotoxicity: Safety compared with trastuzumab [J ] . Future Oncol , 2015 , 11 ( 1 ): 13 - 15 . DOI: 10.2217/fon.14.184 http://doi.org/10.2217/fon.14.184

LEES C , YAZDAN-ASHOORI P , JERZAK K J , et al. Takotsubo cardiomyopathy during anti-HER2 therapy for metastatic breast cancer [J ] . Oncol , 2019 , 24 ( 2 ): e80 - e82 . DOI: 10.1634/theoncologist.2018-0285 http://doi.org/10.1634/theoncologist.2018-0285 https://academic.oup.com/oncolo/article/24/2/e80/6439123 https://academic.oup.com/oncolo/article/24/2/e80/6439123

CHOI H D , CHANG M J . Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: A meta-analysis [J ] . Breast Cancer Res Treat , 2017 , 166 ( 3 ): 927 - 936 . DOI: 10.1007/s10549-017-4460-9 http://doi.org/10.1007/s10549-017-4460-9 http://link.springer.com/10.1007/s10549-017-4460-9 http://link.springer.com/10.1007/s10549-017-4460-9

GUAN Z Z , XU B H , DESILVIO M L , et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer [J ] . J Clin Oncol , 2013 , 31 ( 16 ): 1947 - 1953 . DOI: 10.1200/JCO.2011.40.5241 http://doi.org/10.1200/JCO.2011.40.5241

CHAN A , DELALOGE S , HOLMES F A , et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J ] . Lancet Oncol , 2016 , 17 ( 3 ): 367 - 377 . DOI: S1470-2045(15)00551-3 http://doi.org/S1470-2045(15)00551-3

PARK J W , LIU M C , YEE D , et al. Adaptive randomization of neratinib in early breast cancer [J ] . N Engl J Med , 2016 , 375 ( 1 ): 11 - 22 . DOI: 10.1056/NEJMoa1513750 http://doi.org/10.1056/NEJMoa1513750 http://www.nejm.org/doi/10.1056/NEJMoa1513750 http://www.nejm.org/doi/10.1056/NEJMoa1513750

BURSTEIN H J , SUN Y , DIRIX L Y , et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer [J ] . J Clin Oncol , 2010 , 28 ( 8 ): 1301 - 1307 . DOI: 10.1200/JCO.2009.25.8707 http://doi.org/10.1200/JCO.2009.25.8707

XUHONG J C , QI X W , ZHANG Y , et al. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer [J ] . Am J Cancer Res , 2019 , 9 ( 10 ): 2103 - 2119 .

PONDÉ N , AMEYE L , LAMBERTINI M , et al. Trastuzumab emtansine(T-DM1)-associated cardiotoxicity: pooled analysis in advanced HER2-positive breast cancer [J ] . Eur J Cancer , 2020 , 126 : 65 - 73 . DOI: 10.1016/j.ejca.2019.11.023 http://doi.org/10.1016/j.ejca.2019.11.023 https://linkinghub.elsevier.com/retrieve/pii/S0959804919308718 https://linkinghub.elsevier.com/retrieve/pii/S0959804919308718

THEIN K Z , BALL S , ZAW M H , et al. Updated meta-analysis of randomized controlled trials (RCTs) to determine the CDK 4/6 inhibitors associated venous thromboembolism (VTE) risk in hormone receptor-positive breast cancer (BC) patients [J ] . Ann Oncol , 2018 , 29 : viii606 .

INFANTE J R , CASSIER P A , GERECITANO J F , et al. A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas [J ] . Clin Cancer Res , 2016 , 22 ( 23 ): 5696 - 5705 .

BONACA M P , OLENCHOCK B A , SALEM J E , et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology [J ] . Circulation , 2019 , 140 ( 2 ): 80 - 91 .

HU J R , FLORIDO R , LIPSON E J , et al. Cardiovascular toxicities associated with immune checkpoint inhibitors [J ] . Cardiovasc Res , 2019 , 115 ( 5 ): 854 - 868 . DOI: 10.1093/cvr/cvz026 http://doi.org/10.1093/cvr/cvz026 https://academic.oup.com/cardiovascres/article/115/5/854/5304411 https://academic.oup.com/cardiovascres/article/115/5/854/5304411

SCHMID P , ADAMS S , RUGO H S , et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer [J ] . N Engl J Med , 2018 , 379 ( 22 ): 2108 - 2121 . DOI: 10.1056/NEJMoa1809615 http://doi.org/10.1056/NEJMoa1809615 http://www.nejm.org/doi/10.1056/NEJMoa1809615 http://www.nejm.org/doi/10.1056/NEJMoa1809615

SCHMID P , CORTES J , PUSZTAI L , et al. Pembrolizumab for early triple-negative breast cancer [J ] . N Engl J Med , 2020 , 382 ( 9 ): 810 - 821 . DOI: 10.1056/NEJMoa1910549 http://doi.org/10.1056/NEJMoa1910549 http://www.nejm.org/doi/10.1056/NEJMoa1910549 http://www.nejm.org/doi/10.1056/NEJMoa1910549

THIBAULT C , VANO Y , SOULAT G , et al. Immune checkpoint inhibitors myocarditis: Not all cases are clinically patent [J ] . Eur Heart J , 2018 , 39 ( 38 ): 3553 . DOI: 10.1093/eurheartj/ehy485 http://doi.org/10.1093/eurheartj/ehy485

中国抗癌协会整合肿瘤心脏病学分会 , 中华医学会心血管病学分会肿瘤心脏病学学组 , 中国医师协会心血管内科医师分会肿瘤心脏病学专业委员会 , 等 . 免疫检查点抑制剂相关心肌炎监测与管理中国专家共识(2020版) [J ] . 中国肿瘤临床 , 2020 , 47 ( 20 ): 1027 - 1038 .

Integrated Cancer Cardiology Branch of China Anti Cancer Association , Cancer Cardiology Group of Cardiovascular Branch of Chinese Medical Association , Cancer Cardiology Professional Committee of Cardiovascular Physicians Branch of Chinese Medical Association , et al. Chinese expert consensus on the surveillance and management of immune checkpoint inhibitor-related myocarditis (2020 version) [J ] . Cancer Biol Med , 2020 , 47 ( 20 ): 1027 - 1038 .

THOMPSON J A , SCHNEIDER B J , BRAHMER J , et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology [J ] . J Natl Compr Canc Netw , 2022 , 20 ( 4 ): 387 - 405 . DOI: 10.6004/jnccn.2022.0020 http://doi.org/10.6004/jnccn.2022.0020 https://jnccn.org/view/journals/jnccn/20/4/article-p387.xml https://jnccn.org/view/journals/jnccn/20/4/article-p387.xml

REID P D , CIFU A S , BASS A R . Management of immunotherapy-related toxicities in patients treated with immune checkpoint inhibitor therapy [J ] . JAMA , 2021 , 325 ( 5 ): 482 - 483 . DOI: 10.1001/jama.2020.17308 http://doi.org/10.1001/jama.2020.17308

中国乳腺癌内分泌治疗多学科管理血脂异常管理共识专家组 . 绝经后早期乳腺癌患者血脂异常管理的中国专家共识 [J ] . 中华肿瘤杂志 , 2017 , 39 ( 1 ): 72 - 77 .

China breast cancer Endocrine Therapy Multidisciplinary Management Lipid Abnormality Management Consensus Expert Group . China expert consensus on the management of dyslipidemia in postmenopausal patients with early- stage breast cancer [J ] . Chin J Oncol , 2017 , 39 ( 1 ): 72 - 77 .

COOMBES R C , KILBURN L S , SNOWDON C F , et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial [J ] . Lancet , 2007 , 369 ( 9561 ): 559 - 570 .

BOCCARDO F , RUBAGOTTI A , PUNTONI M , et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian tamoxifen anastrozole trial [J ] . J Clin Oncol , 2005 , 23 ( 22 ): 5138 - 5147 .

ARIMIDEX T , BUZDAR A , HOWELL A , et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial [J ] . Lancet Oncol , 2006 , 7 ( 8 ): 633 - 643 .

COATES A S , KESHAVIAH A , THÜRLIMANN B , et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 [J ] . J Clin Oncol , 2007 , 25 ( 5 ): 486 - 492 .

GOSS P E , INGLE J N , PRITCHARD K I , et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: Ncic ctg ma.27: a randomized controlled phase Ⅲ trial [J ] . J Clin Oncol , 2013 , 31 ( 11 ): 1398 - 1404 . DOI: 10.1200/JCO.2012.44.7805 http://doi.org/10.1200/JCO.2012.44.7805 https://ascopubs.org/doi/10.1200/JCO.2012.44.7805 https://ascopubs.org/doi/10.1200/JCO.2012.44.7805

HOWELL A , ROBERTSON J F , QUARESMA ALBANO J , et al. Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment [J ] . J Clin Oncol , 2002 , 20 ( 16 ): 3396 - 3403 . DOI: 10.1200/JCO.2002.10.057 http://doi.org/10.1200/JCO.2002.10.057 https://ascopubs.org/doi/10.1200/JCO.2002.10.057 https://ascopubs.org/doi/10.1200/JCO.2002.10.057

OSBORNE C K , PIPPEN J , JONES S E , et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial [J ] . J Clin Oncol , 2002 , 20 ( 16 ): 3386 - 3395 .

WANG X , ZHU A J , WANG J Y , et al. Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study [J ] . Ther Adv Med Oncol , 2020 , 12 : 1758835920925991.

MARKOPOULOS C , POLYCHRONIS A , DAFNI U , et al. Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy [J ] . Ann Oncol , 2009 , 20 ( 1 ): 49 - 55 . DOI: 10.1093/annonc/mdn545 http://doi.org/10.1093/annonc/mdn545

CAMERINI A , RONDINI M , GARRONE O , et al. Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients [J ] . Cancer Biol Ther , 2009 , 8 ( 15 ): 1450 - 1455 .

GOEDEGEBUURE W J , VAN DER STEEN M , KERKHOF G F , et al. Longitudinal study on metabolic health in adults SGA during 5 years after GH with or without 2 years of GnRHa treatment [J ] . J Clin Endocrinol Metab , 2020 , 105 ( 8 ): dgaa287 .

YANNUCCI J , MANOLA J , GARNICK M B , et al. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters [J ] . J Urol , 2006 , 176 ( 2 ): 520 - 525 . DOI: 10.1016/j.juro.2006.03.057 http://doi.org/10.1016/j.juro.2006.03.057

诸骏仁 , 高润霖 , 赵水平 , 等 . 中国成人血脂异常防治指南(2016年修订版) [J ] . 中国循环杂志 , 2016 , 31 ( 10 ): 937 - 953 .

ZHU J R , GAO R L , ZHAO S P , et al. Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (revised in 2016) [J ] . Chin Circ J , 2016 , 31 ( 10 ): 937 - 953 .

TAUNK N K , HAFFTY B G , KOSTIS J B , et al. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms [J ] . Front Oncol , 2015 , 5 : 39 . DOI: 10.3389/fonc.2015.00039 http://doi.org/10.3389/fonc.2015.00039

SOUMAROVÁ R , RUŠINOVÁ L . Cardiotoxicity of breast cancer radiotherapy-overview of current results [J ] . Rep Pract Oncol Radiother , 2020 , 25 ( 2 ): 182 - 186 . DOI: 10.1016/j.rpor.2019.12.008 http://doi.org/10.1016/j.rpor.2019.12.008 https://linkinghub.elsevier.com/retrieve/pii/S1507136719301075 https://linkinghub.elsevier.com/retrieve/pii/S1507136719301075

CLARKE M , COLLINS R , DARBY S , et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials [J ] . Lancet , 2005 , 366 ( 9503 ): 2087 - 2106 . DOI: 10.1016/S0140-6736(05)67887-7 http://doi.org/10.1016/S0140-6736(05)67887-7

HENSON K E , MCGALE P , TAYLOR C , et al. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer [J ] . Br J Cancer , 2013 , 108 ( 1 ): 179 - 182 . DOI: 10.1038/bjc.2012.575 http://doi.org/10.1038/bjc.2012.575 https://doi.org/10.1038/bjc.2012.575 https://doi.org/10.1038/bjc.2012.575

CHENG Y J , NIE X Y , JI C C , et al. Long-term cardiovascular risk after radiotherapy in women with breast cancer [J ] . J Am Heart Assoc , 2017 , 6 ( 5 ): e005633 . DOI: 10.1161/JAHA.117.005633 http://doi.org/10.1161/JAHA.117.005633 https://www.ahajournals.org/doi/10.1161/JAHA.117.005633 https://www.ahajournals.org/doi/10.1161/JAHA.117.005633

LANCELLOTTI P , NKOMO V T , BADANO L P , et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography [J ] . Eur Heart J Cardiovasc Imaging , 2013 , 14 ( 8 ): 721 - 740 . DOI: 10.1093/ehjci/jet123 http://doi.org/10.1093/ehjci/jet123

SAIKI H , PETERSEN I A , SCOTT C G , et al. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer [J ] . Circulation , 2017 , 135 ( 15 ): 1388 - 1396 . DOI: 10.1161/CIRCULATIONAHA.116.025434 http://doi.org/10.1161/CIRCULATIONAHA.116.025434

DARBY S C , EWERTZ M , MCGALE P , et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer [J ] . N Engl J Med , 2013 , 368 ( 11 ): 987 - 998 . DOI: 10.1056/NEJMoa1209825 http://doi.org/10.1056/NEJMoa1209825 http://www.nejm.org/doi/10.1056/NEJMoa1209825 http://www.nejm.org/doi/10.1056/NEJMoa1209825

TAYLOR C , CORREA C , DUANE F K , et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials [J ] . J Clin Oncol , 2017 , 35 ( 15 ): 1641 - 1649 . DOI: 10.1200/JCO.2016.72.0722 http://doi.org/10.1200/JCO.2016.72.0722

NILSSON G , HOLMBERG L , GARMO H , et al. Distribution of coronary artery stenosis after radiation for breast cancer [J ] . J Clin Oncol , 2012 , 30 ( 4 ): 380 - 386 . DOI: 10.1200/JCO.2011.34.5900 http://doi.org/10.1200/JCO.2011.34.5900

LO Q , HEE L A , BATUMALAI V , et al. Strain imaging detects dose-dependent segmental cardiac dysfunction in the acute phase after breast irradiation [J ] . Int J Radiat Oncol Biol Phys , 2017 , 99 ( 1 ): 182 - 190 . DOI: 10.1016/j.ijrobp.2017.05.030 http://doi.org/10.1016/j.ijrobp.2017.05.030 https://linkinghub.elsevier.com/retrieve/pii/S0360301617309641 https://linkinghub.elsevier.com/retrieve/pii/S0360301617309641

VAN DEN BOGAARD V A , TA B D , et al. VAN DER SCHAAF A, Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures [J ] . J Clin Oncol , 2017 , 35 ( 11 ): 1171 - 1178 . DOI: 10.1200/JCO.2016.69.8480 http://doi.org/10.1200/JCO.2016.69.8480

ZAGAR T M , KAIDAR-PERSON O , TANG X L , et al. Utility of deep inspiration breath hold for left-sided breast radiation therapy in preventing early cardiac perfusion defects: a prospective study [J ] . Int J Radiat Oncol Biol Phys , 2017 , 97 ( 5 ): 903 - 909 . DOI: 10.1016/j.ijrobp.2016.12.017 http://doi.org/10.1016/j.ijrobp.2016.12.017 https://linkinghub.elsevier.com/retrieve/pii/S036030161633557X https://linkinghub.elsevier.com/retrieve/pii/S036030161633557X

CHANG J S , CHEN J , WEINBERG V K , et al. Evaluation of heart dose for left-sided breast cancer patients over an 11-year period spanning the transition from 2-dimensional to 3-dimensional planning [J ] . Clin Breast Cancer , 2016 , 16 ( 5 ): 396 - 401 . DOI: S1526-8209(16)30109-4 http://doi.org/S1526-8209(16)30109-4

REMOUCHAMPS V M , VICINI F A , SHARPE M B , et al. Significant reductions in heart and lung doses using deep inspiration breath hold with active breathing control and intensity-modulated radiation therapy for patients treated with locoregional breast irradiation [J ] . Int J Radiat Oncol Biol Phys , 2003 , 55 ( 2 ): 392 - 406 . DOI: 10.1016/S0360-3016(02)04143-3 http://doi.org/10.1016/S0360-3016(02)04143-3 https://linkinghub.elsevier.com/retrieve/pii/S0360301602041433 https://linkinghub.elsevier.com/retrieve/pii/S0360301602041433

GOYAL U , SABODA K , ROE D , et al. Prone positioning with deep inspiration breath hold for left breast radiotherapy [J ] . Clin Breast Cancer , 2021 , 21 ( 4 ): e295 - e301 . DOI: 10.1016/j.clbc.2020.11.004 http://doi.org/10.1016/j.clbc.2020.11.004

TAYLOR C W , WANG Z , MACAULAY E , et al. Exposure of the heart in breast cancer radiation therapy: a systematic review of heart doses published during 2003 to 2013 [J ] . Int J Radiat Oncol Biol Phys , 2015 , 93 ( 4 ): 845 - 853 . DOI: 10.1016/j.ijrobp.2015.07.2292 http://doi.org/10.1016/j.ijrobp.2015.07.2292 https://linkinghub.elsevier.com/retrieve/pii/S036030161503103X https://linkinghub.elsevier.com/retrieve/pii/S036030161503103X

MACDONALD S M , JIMENEZ R , PAETZOLD P , et al. Proton radiotherapy for chest wall and regional lymphatic radiation; dose comparisons and treatment delivery [J ] . Radiat Oncol , 2013 , 8 : 71 . DOI: 10.1186/1748-717X-8-71 http://doi.org/10.1186/1748-717X-8-71

ZAMORANO J L , LANCELLOTTI P , RODRIGUEZ MUÑOZ D , et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines [J ] . Eur J Heart Fail , 2017 , 19 ( 1 ): 9 - 42 . DOI: 10.1002/ejhf.654 http://doi.org/10.1002/ejhf.654 https://onlinelibrary.wiley.com/doi/10.1002/ejhf.654 https://onlinelibrary.wiley.com/doi/10.1002/ejhf.654

NELLESSEN U , ZINGEL M , HECKER H , et al. Effects of radiation therapy on myocardial cell integrity and pump function: which role for cardiac biomarkers? [J ] . Chemotherapy , 2010 , 56 ( 2 ): 147 - 152 . DOI: 10.1159/000313528 http://doi.org/10.1159/000313528

SKYTTÄ T , TUOHINEN S , BOMAN E , et al. Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy [J ] . Radiat Oncol , 2015 , 10 : 141 . DOI: 10.1186/s13014-015-0436-2 http://doi.org/10.1186/s13014-015-0436-2

DEVEREAUX P J , GOLDMAN L , COOK D J , et al. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk [J ] . CMAJ , 2005 , 173 ( 6 ): 627 - 634 .

FLEISHER L A , FLEISCHMANN K E , AUERBACH A D , et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Developed in collaboration with the American College of Surgeons, American Society of Anesthesiologists, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Anesthesiologists, and Society of Vascular Medicine Endorsed by the Society of Hospital Medicine [J ] . J Nucl Cardiol , 2015 , 22 : 162 - 215 . DOI: 10.1007/s12350-014-0025-z http://doi.org/10.1007/s12350-014-0025-z http://link.springer.com/10.1007/s12350-014-0025-z http://link.springer.com/10.1007/s12350-014-0025-z

JENSEN B V . Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer [J ] . Semin Oncol , 2006 , 33 ( < W > 3 Suppl 8 ): S15 - S21 . DOI: 10.1053/j.seminoncol.2006.08.003 http://doi.org/10.1053/j.seminoncol.2006.08.003 https://linkinghub.elsevier.com/retrieve/pii/S0093775406003149 https://linkinghub.elsevier.com/retrieve/pii/S0093775406003149

OKAMOTO T , OGATA J , MINAMI K . Sino-atrial block during anesthesia in a patient with breast cancer being treated with the anticancer drug epirubicin [J ] . Anesth Analg , 2003 , 97 ( 1 ): 19 - 20 , tableofcontents.

HUETTEMANN E , JUNKER T , CHATZINIKOLAOU K P , et al. The influence of anthracycline therapy on cardiac function during anesthesia [J ] . Anesth Analg , 2004 , 98 ( 4 ): 941 - 947 . DOI: 10.1213/01.ANE.0000108135.52036.48 http://doi.org/10.1213/01.ANE.0000108135.52036.48

KOJIMA A , KITAGAWA H , OMATSU-KANBE M , et al. Sevoflurane protects ventricular myocytes against oxidative stress-induced cellular Ca2+ overload and hypercontracture [J ] . Anesthesiology , 2013 , 119 ( 3 ): 606 - 620 . DOI: 10.1097/ALN.0b013e318292ee52 http://doi.org/10.1097/ALN.0b013e318292ee52

樊理华 , 韩新 , 陈琴 . 七氟烷对术前化疗患者心肌细胞的影响 [J ] . 浙江医学 , 2013 , 35 ( 15 ): 1422 - 1423 .

FAN L H , HAN X , CHEN Q . Sevoflurane does not aggravate myocardial injury induced by preoperative chemotherapy [J ] . Zhejiang Med J , 2013 , 35 ( 15 ): 1422 - 1423 .

赵光瑜 , 王永顺 , 代冬梅 , 陈筠 . 乳腺癌患者术前化疗及不同麻醉方法对血液流变学的影响 [J ] . 临床麻醉学杂志 , 2002 , 18 ( 3 ): 124 - 126 .

ZHAO G Y , WANG Y S , DAI D M , et al. Effects of anesthesia on hemorheology in breast cancer patient underwent chemotherapy [J ] . J Clin Anesth , 2002 , 18 ( 3 ): 124 - 126 . DOI: 10.1016/j.jclinane.2005.08.013 http://doi.org/10.1016/j.jclinane.2005.08.013 https://linkinghub.elsevier.com/retrieve/pii/S0952818005003582 https://linkinghub.elsevier.com/retrieve/pii/S0952818005003582

KRISTENSEN S D , KNUUTI J , SARASTE A , et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The joint task force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA) [J ] . Eur Heart J , 2014 , 35 ( 35 ): 2383 - 2431 . DOI: 10.1093/eurheartj/ehu282 http://doi.org/10.1093/eurheartj/ehu282 https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehu282 https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehu282

LARSEN C M , MULVAGH S L . Cardio-oncology: What you need to know now for clinical practice and echocardiography [J ] . Echo Res Pract , 2017 , 4 ( 1 ): R33 - R41 . DOI: 10.1530/ERP-17-0013 http://doi.org/10.1530/ERP-17-0013 https://erp.bioscientifica.com/view/journals/echo/4/1/R33.xml https://erp.bioscientifica.com/view/journals/echo/4/1/R33.xml

CURIGLIANO G , CARDINALE D , SUTER T , et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines [J ] . Ann Oncol , 2012 , 23 ( Suppl 7 ): vii155 - vii166 . DOI: 10.1093/annonc/mds293 http://doi.org/10.1093/annonc/mds293 https://linkinghub.elsevier.com/retrieve/pii/S0923753419376744 https://linkinghub.elsevier.com/retrieve/pii/S0923753419376744

VIRANI S A , DENT S , BREZDEN-MASLEY C , et al. Canadian cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapy [J ] . Can J Cardiol , 2016 , 32 ( 7 ): 831 - 841 . DOI: 10.1016/j.cjca.2016.02.078 http://doi.org/10.1016/j.cjca.2016.02.078

CURIGLIANO G , LENIHAN D , FRADLEY M , et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations [J ] . Ann Oncol , 2020 , 31 ( 2 ): 171 - 190 . DOI: S0923-7534(19)36080-6 http://doi.org/S0923-7534(19)36080-6

SUN J P , POPOVIĆ Z B , GREENBERG N L , et al. Noninvasive quantification of regional myocardial function using Doppler-derived velocity, displacement, strain rate, and strain in healthy volunteers: effects of aging [J ] . J Am Soc Echocardiogr , 2004 , 17 ( 2 ): 132 - 138 . DOI: 10.1016/j.echo.2003.10.001 http://doi.org/10.1016/j.echo.2003.10.001 https://linkinghub.elsevier.com/retrieve/pii/S0894731703008447 https://linkinghub.elsevier.com/retrieve/pii/S0894731703008447

JORDAN J H , SUKPRAPHRUTE B , MELÉNDEZ G C , et al. Early myocardial strain changes during potentially cardiotoxic chemotherapy may occur as a result of reductions in left ventricular end-diastolic volume: The need to interpret left ventricular strain with volumes [J ] . Circulation , 2017 , 135 ( 25 ): 2575 - 2577 . DOI: 10.1161/CIRCULATIONAHA.117.027930 http://doi.org/10.1161/CIRCULATIONAHA.117.027930

MELÉNDEZ G C , SUKPRAPHRUTE B , D'AGOSTINO R B Jr , et al. Frequency of left ventricular end-diastolic volume-mediated declines in ejection fraction in patients receiving potentially cardiotoxic cancer treatment [J ] . Am J Cardiol , 2017 , 119 ( 10 ): 1637 - 1642 . DOI: S0002-9149(17)30194-7 http://doi.org/S0002-9149(17)30194-7

FALLAH-RAD N , WALKER J R , WASSEF A , et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy [J ] . J Am Coll Cardiol , 2011 , 57 ( 22 ): 2263 - 2270 . DOI: 10.1016/j.jacc.2010.11.063 http://doi.org/10.1016/j.jacc.2010.11.063 https://linkinghub.elsevier.com/retrieve/pii/S073510971100979X https://linkinghub.elsevier.com/retrieve/pii/S073510971100979X

NEGISHI K , NEGISHI T , HALUSKA B A , et al. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection [J ] . Eur Heart J Cardiovasc Imaging , 2014 , 15 ( 3 ): 324 - 331 . DOI: 10.1093/ehjci/jet159 http://doi.org/10.1093/ehjci/jet159

SAWAYA H , SEBAG I A , PLANA J C , et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab [J ] . Circ Cardiovasc Imaging , 2012 , 5 ( 5 ): 596 - 603 . DOI: 10.1161/CIRCIMAGING.112.973321 http://doi.org/10.1161/CIRCIMAGING.112.973321

SANTORO C , ARPINO G , ESPOSITO R , et al. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility [J ] . Eur Heart J Cardiovasc Imaging , 2017 , 18 ( 8 ): 930 - 936 . DOI: 10.1093/ehjci/jex033 http://doi.org/10.1093/ehjci/jex033

CHANG W T , SHIH J Y , FENG Y H , et al. The early predictive value of right ventricular strain in epirubicin-induced cardiotoxicity in patients with breast cancer [J ] . Acta Cardiol Sin , 2016 , 32 ( 5 ): 550 - 559 .

LANG R M , BADANO L P , MOR-AVI V , et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging [J ] . Eur Heart J Cardiovasc Imaging , 2015 , 16 ( 3 ): 233 - 270 . DOI: 10.1093/ehjci/jev014 http://doi.org/10.1093/ehjci/jev014

BERGAMINI C , DOLCI G , ROSSI A , et al. Left atrial volume in patients with HER2-positive breast cancer: one step further to predict trastuzumab-related cardiotoxicity [J ] . Clin Cardiol , 2018 , 41 ( 3 ): 349 - 353 . DOI: 10.1002/clc.22872 http://doi.org/10.1002/clc.22872

TOTZECK M , SCHULER M , STUSCHKE M , et al. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease [J ] . Int J Cardiol , 2019 , 280 : 163 - 175 . DOI: S0167-5273(18)35860-1 http://doi.org/S0167-5273(18)35860-1

FRADLEY M G , MOSLEHI J . QT prolongation and oncology drug development [J ] . Card Electrophysiol Clin , 2015 , 7 ( 2 ): 341 - 355 . DOI: 10.1016/j.ccep.2015.03.013 http://doi.org/10.1016/j.ccep.2015.03.013

HORTOBAGYI G N , STEMMER S M , BURRIS H A , et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer [J ] . N Engl J Med , 2016 , 375 ( 18 ): 1738 - 1748 . DOI: 10.1056/NEJMoa1609709 http://doi.org/10.1056/NEJMoa1609709 http://www.nejm.org/doi/10.1056/NEJMoa1609709 http://www.nejm.org/doi/10.1056/NEJMoa1609709

THYGESEN K , ALPERT J S , JAFFE A S , et al. Fourth universal definition of myocardial infarction (2018) [J ] . Circulation , 2018 , 138 ( 20 ): e618 - e651 .

TWERENBOLD R , BOEDDINGHAUS J , NESTELBERGER T , et al. Clinical use of high-sensitivity cardiac troponin in patients with suspected myocardial infarction [J ] . J Am Coll Cardiol , 2017 , 70 ( 8 ): 996 - 1012 . DOI: S0735-1097(17)38777-6 http://doi.org/S0735-1097(17)38777-6

MAIR J , LINDAHL B , MÜLLER C , et al. What to do when you question cardiac troponin values [J ] . Eur Heart J Acute Cardiovasc Care , 2018 , 7 ( 6 ): 577 - 586 . DOI: 10.1177/2048872617708973 http://doi.org/10.1177/2048872617708973

BERRY G J , JORDEN M . Pathology of radiation and anthracycline cardiotoxicity [J ] . Pediatr Blood Cancer , 2005 , 44 ( 7 ): 630 - 637 .

GOLDHAR H A , YAN A T , KO D T , et al. The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: a population study [J ] . J Natl Cancer Inst , 2016 , 108 ( 1 ): djv301 . DOI: 10.1093/jnci/djv301 http://doi.org/10.1093/jnci/djv301 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djv301 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djv301

CHOW E J , BAKER K S , LEE S J , et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation [J ] . J Clin Oncol , 2014 , 32 ( 3 ): 191 - 198 . DOI: 10.1200/JCO.2013.52.6582 http://doi.org/10.1200/JCO.2013.52.6582

ADVANI P P , BALLMAN K V , DOCKTER T J , et al. Long-term cardiac safety analysis of NCCTG N9831 (alliance) adjuvant trastuzumab trial [J ] . J Clin Oncol , 2016 , 34 ( 6 ): 581 - 587 . DOI: 10.1200/JCO.2015.61.8413 http://doi.org/10.1200/JCO.2015.61.8413

PINDER M C , DUAN Z G , GOODWIN J S , et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer [J ] . J Clin Oncol , 2007 , 25 ( 25 ): 3808 - 3815 .

CARDINALE D , COLOMBO A , BACCHIANI G , et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy [J ] . Circulation , 2015 , 131 ( 22 ): 1981 - 1988 . DOI: 10.1161/CIRCULATIONAHA.114.013777 http://doi.org/10.1161/CIRCULATIONAHA.114.013777

CARDINALE D , COLOMBO A , LAMANTIA G , et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy [J ] . J Am Coll Cardiol , 2010 , 55 ( 3 ): 213 - 220 . DOI: 10.1016/j.jacc.2009.03.095 http://doi.org/10.1016/j.jacc.2009.03.095

ARMENIAN S H , LACCHETTI C , BARAC A , et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline [J ] . J Clin Oncol , 2017 , 35 ( 8 ): 893 - 911 . DOI: 10.1200/JCO.2016.70.5400 http://doi.org/10.1200/JCO.2016.70.5400

KIKUCHI R , SHAH N P , DENT S F . Strategies to prevent cardiovascular toxicity in breast cancer: is it ready for primetime? [J ] . J Clin Med , 2020 , 9 ( 4 ): 896 . DOI: 10.3390/jcm9040896 http://doi.org/10.3390/jcm9040896 https://www.mdpi.com/2077-0383/9/4/896 https://www.mdpi.com/2077-0383/9/4/896

AVILA M S , AYUB-FERREIRA S M , DE BARROS WANDERLEY M R Jr , et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial [J ] . J Am Coll Cardiol , 2018 , 71 ( 20 ): 2281 - 2290 . DOI: S0735-1097(18)33480-6 http://doi.org/S0735-1097(18)33480-6

BOEKHOUT A H , GIETEMA J A , MILOJKOVIC KERKLAAN B , et al. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial [J ] . JAMA Oncol , 2016 , 2 ( 8 ): 1030 - 1037 . DOI: 10.1001/jamaoncol.2016.1726 http://doi.org/10.1001/jamaoncol.2016.1726

GULATI G , HECK S L , REE A H , et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol [J ] . Eur Heart J , 2016 , 37 ( 21 ): 1671 - 1680 . DOI: 10.1093/eurheartj/ehw022 http://doi.org/10.1093/eurheartj/ehw022

PITUSKIN E , MACKEY J R , KOSHMAN S , et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity [J ] . J Clin Oncol , 2017 , 35 ( 8 ): 870 - 877 . DOI: 10.1200/JCO.2016.68.7830 http://doi.org/10.1200/JCO.2016.68.7830

GUGLIN M , KRISCHER J , TAMURA R , et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer [J ] . J Am Coll Cardiol , 2019 , 73 ( 22 ): 2859 - 2868 .

GEUNA E , LOMBARDI P , MARTINELLO R , et al. Treatment with beta-blockers and ACE-inhibitors in breast cancer patients receiving adjuvant trastuzumab-based therapy and developing mild cardiac toxicity: a prospective study [J ] . Cancers (Basel) , 2020 , 12 ( 2 ): E327 .

中国抗癌协会乳腺癌专业委员会 . 中国抗癌协会乳腺癌诊治指南与规范(2021年版) [J ] . 中国癌症杂志 , 2021 , 31 ( 10 ): 954 - 1040 .

The Society of Breast Cancer China Anti-Cancer Association . Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2021 edition) [J ] . China Oncol , 2021 , 31 ( 10 ): 954 - 1040 .

Views

9058

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)

Expert consensus on BRCA1/2 gene testing and clinical application in Chinese breast cancer patients (2025 edition)

Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2024 edition)

New progress and prospect of breast cancer bone metastasis research from mechanism to clinic

Targeting DNA damage response deficiency in the treatment of breast cancer

Related Author

The Society of Breast Cancer China Anti-Cancer Association

Breast Oncology Group of the Oncology Branch of the Chinese Medical Association

Hongxia WANG

Yongmei YIN

Xichun HU

Breast Cancer China Anti-Cancer Association The Society of

of the Oncology Branch of the Chinese Medical Association Breast Oncology Group

Jiahui WANG

Related Institution

Committee of Breast Cancer Society, Chinese Anti-Cancer Association; Clinical Precision Medicine Professional Committee, Chinese Medical Doctor Association; Tumor Heterogeneity and Personalized Therapy Professional Committee, Chinese Anti-Cancer Association

上海交通大学附属第六人民医院肿瘤内科

Phase Ⅰ Clinical Trial Center, Fudan University Shanghai Cancer Center; Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

南京医科大学

南京医科大学第一附属医院肿瘤科

AI问答

⁰